Amarin | AMRN - Debt

Stock Price
14.31
Daily Change
-0.28 -1.92%
Monthly
-2.52%
Yearly
37.20%
Q2 Forecast
13.88

Amarin reported $0 in Debt for its fiscal quarter ending in March of 2025.





Debt Change Date
AbbVie USD 1000K 70.48B Sep/2025
Alnylam Pharmaceuticals USD 1.31B 11.39M Sep/2025
Amarin USD 0 0 Mar/2025
AstraZeneca USD 32.63B 207M Sep/2025
BioCryst Pharmaceuticals USD 828.6M 510K Dec/2024
DBV Technologies USD 8.59M 295K Sep/2025
Esperion Therapeutics USD 262.92M 1.76M Sep/2024
GlaxoSmithKline GBP 17.75B 396M Sep/2025
Halozyme Therapeutics USD 1.51B 1.66M Sep/2025
Heron Therapeutics USD 149.65M 157K Sep/2024
Ionis Pharmaceuticals USD 2.33B 1.1B Dec/2025
Nektar Therapeutics USD 0 0 Jun/2022
Neurocrine Biosciences USD 428.4M 10.7M Sep/2025
Novartis USD 32.64B 1.37B Jun/2025